It was approved for treating post-menopausal women with osteoporosis in 1999 and in 2007, the FDA approved raloxifene for reducing the risk of invasive breast cancer in post-menopausal women with osteoporosis or at high risk for invasive breast cancer.
http://ift.tt/eA8V8J
0 comments:
Post a Comment